Drug Profile
HGP 32
Latest Information Update: 08 Feb 2008
Price :
$50
*
At a glance
- Originator HG Pars
- Class Antiglaucomas
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 30 Jul 1998 No-Development-Reported for Glaucoma in USA (Unknown route)
- 17 Apr 1996 New profile